These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
    Author: Tobío A, Alfonso A, Botana LM.
    Journal: Anticancer Res; 2014 Jul; 34(7):3347-56. PubMed ID: 24982339.
    Abstract:
    AIM: The aim of the present study was to determine the relationship between the tyrosine kinase inhibitors, STI571 and dasatinib effects and protein kinase C (PKC) status in HMC-1(560) and HMC-1(560,816) cell lines. MATERIAL AND METHODS: Viability results were obtained by two different methods: MTT and a flow cytometry with Annexin V-FITC/PI double-staining protocol. The lipid-based transfection method was used to silence PKC. RESULTS: Long-term PKC activation induces apoptosis in both HMC-1 cell lines. Moreover, PKC activation potentiates STI571 and dasatinib cytotoxic effects in HMC-1(560) and HMC-1(560,816) cells, respectively, by increasing necrotic populations. To investigate this PKC effect, the role of PKCδ, an isoform intimately related with apoptotic cell death, was studied. The results obtained evidence that either STI571 or dasatinib apoptotic cell death are PKCδ-dependent. Particularly, STI571 showed less dependence to PKCδ than dasatinib. CONCLUSION: PKCδ modulation is essential and determines mastocytosis treatment effectiveness, since STI571 and dasatinib effects are PKCδ-dependent.
    [Abstract] [Full Text] [Related] [New Search]